CAC 40
8 067,13 -24,73 (-0,31 %) Euro Stoxx 50
4 969,62 -20,26 (-0,41 %) Dow Jones
38 460,92 -42,77 (-0,11 %) EUR/USD
1,0719 +0,0018 (+0,17 %) Gold future
2 334,10 -4,30 (-0,18 %) Bitcoin EUR
59 929,74 -2 398,37 (-3,85 %)
BioMarin Pharmaceutical Inc. (BMRN)
Échanges après Bourse :
BioMarin Pharmaceutical Inc.
770 Lindaro Street
San Rafael, CA 94901
United States
415 506 6700
https://www.biomarin.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 3 401
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Alexander Hardy | President, CEO & Director | 1,72M | S.O. | 1969 |
| Mr. Brian R. Mueller | CFO & Executive VP | 1,07M | 2,47M | 1974 |
| Dr. C. Greg Guyer Ph.D. | Executive VP & Chief Technical Officer | 1,11M | S.O. | 1962 |
| Mr. Jeffrey Robert Ajer | Executive VP & Chief Commercial Officer | 1,1M | S.O. | 1962 |
| Dr. Henry J. Fuchs M.D., Ph.D. | President of Worldwide Research & Development | 1,41M | S.O. | 1958 |
| Ms. Erin Burkhart | Group VP & Chief Accounting Officer | S.O. | S.O. | 1979 |
| Dr. Kevin Eggan Ph.D. | Chief Scientific Officer & Senior VP of Research and Early Development | S.O. | S.O. | S.O. |
| Traci McCarty | Group Vice President of Investor Relations | S.O. | S.O. | S.O. |
| Mr. George Eric Davis | Executive VP, Chief Legal Officer, General Counsel & Secretary | 1,23M | 2,11M | 1971 |
| Ms. Humaira Serajuddin | Senior VP & Chief Marketing Officer | S.O. | S.O. | S.O. |
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Gouvernance d’entreprise
L’ISS Governance QualityScore de BioMarin Pharmaceutical Inc. en date du 1 avril 2024 est 3. Les scores principaux sont Audit : 1; Société : 3; Droits des actionnaires : 5; Compensation : 5.
